Exidavnemab (ABBV-0805; BAN-0805) 是一种人源化 IgG4 单克隆抗体，可选择性靶向可溶性人 α-突触核蛋白(α-synuclein) 聚集体，KD 值为 18.5 pM, 作用于 α-突触核蛋白单体的 KD 值为 2.2 μM。 Exidavnemab 可用于帕金森病研究。
| 生物活性 | Exidavnemab (ABBV-0805; BAN-0805) is a humanIgG4monoclonal antibody that selectively targets soluble humanα-synucleinaggregates with a KD value of 18.5 pM and a KD value of 2.2 μM forα-synucleinmonomers. Exidavnemab is used in Parkinson's disease research[1]. |
体外研究
(In Vitro) | ABBV-0805 enhances mouse primary neuronal cell viability in a dose-dependent manner, with cell viability reaching approximately 81.4 % at high doses[1].
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
